Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

KRAS was called undruggable for forty years, and this week it took another beating. Genentech's divarasib showed superiority over approved therapy in previously treated non small cell lung cancer, which matters for two reasons. First, head to head wins are rare in oncology. Most drugs get approved by beating chemo or placebo, not by beating the current targeted standard, so a G12C inhibitor topping approved therapy is a real statement. Second, it reshapes a competitive field that Amgen's Lumakras opened in 2021 and that Krazati joined soon after. Both of those drugs have underwhelmed commercially relative to the early hype, and divarasib now arrives claiming it can do better. If the full data hold up, Genentech has the best in class G12C drug and the rest of the field has a problem.

Step back and the whole RAS story is the one to watch this year. We spent the spring on Revolution Medicines and its pan RAS drug daraxonrasib, which posted practice changing pancreatic cancer data at ASCO, and its second molecule RM-055. Now Genentech is pushing the narrower G12C approach past the incumbents. Two different bets on the same oncogene, both paying off in the same year, after four decades of failure. That is the kind of arc that defines a decade in cancer drug development, and we will keep tracking who ends up owning which slice of it.

One more thread worth flagging. We have covered the AI drug discovery deal spree all year, from Isomorphic to Insilico to the Anthropic pharma ecosystem. This week Anthropic's own CEO tempered expectations for how fast AI will actually change biology. We think that is healthy. The tools are real and the deals are real, but the timelines the hype cycle promised were never going to hold, and a little realism from the top is better for the field than another round of overpromising. 👉 Read Full Analysis

🔬 Oncology

Genentech just made the case that it has the best KRAS G12C drug in the class. RHHBY

Roche's Genentech unit reported that its KRAS G12C inhibitor divarasib beat approved therapy in a Phase 3 trial in previously treated non small cell lung cancer, according to BioWorld. The G12C mutation drives a meaningful slice of lung cancers, and until now the approved options have been Amgen's Lumakras and the BMS and Mirati drug Krazati, both of which launched to big expectations and delivered modest commercial results. A head to head style win over the approved standard is uncommon and positions divarasib as a potential best in class option. Watch for the full data at an upcoming medical meeting, since the size of the benefit will determine whether this reshuffles prescribing or just adds a third option to the mix.

🏢 M&A

Novartis keeps buying, and this time it is betting on a better ADC payload. NVS

Novartis agreed to acquire UK based Myricx Bio for up to $1.5B, with $1.1B upfront and up to $400M in milestones, according to STAT and The Pharma Letter. The prize is a novel antibody drug conjugate payload platform built on NMT inhibition, a mechanism designed to overcome the resistance that limits current ADC payloads, plus lead programs aimed at B7-H3 and HER2. This is a platform bet rather than a single asset buy, and it fits the pattern we have tracked all year: Novartis has been one of the most active dealmakers in pharma, layering ADCs and molecular glues onto its pipeline. The ADC field has been racing toward new targets, but the payload itself has been a quieter bottleneck, and Novartis is paying to get ahead of it.

🤖 AI and Drug Discovery

The loudest voice in AI just told everyone to slow down.

Anthropic CEO Dario Amodei tempered his own earlier predictions about how quickly AI will transform drug discovery, according to STAT. Coming from someone who has made some of the boldest claims in the space, it is a notable reset. Our read: this is good for the field. We have covered a steady run of AI discovery deals this year, from Insilico and Takeda to the broad Anthropic pharma ecosystem, and the technology is genuinely useful. But the idea that AI would compress a decade of biology into a couple of years was always more pitch than plan. Realistic timelines make for better partnerships and fewer disappointed boards.

🌍 Policy

Medicare reopened the 340B fight.

Medicare proposed steep cuts to 340B drug payments, according to STAT, reigniting a long running battle between hospitals that depend on the discount program and an administration looking to rein in drug spending. The 340B program has ballooned in size and complexity, and any move to cut payments draws immediate pushback from the hospital lobby. For drugmakers, the program remains a persistent source of channel complexity and disputed discounts, so any reform that clarifies the rules could cut both ways. Expect a loud comment period.

📅 Coming Up

👉 Read Full Analysis

For most of the modern era of cancer drug development, KRAS was the target everyone wanted and no one could hit. That changed in 2021 when Amgen's Lumakras became the first approved KRAS G12C inhibitor, followed by Krazati from Mirati, now part of Bristol Myers Squibb. Both were scientific milestones. Neither became the commercial blockbuster the early excitement suggested, held back by modest response durations and a competitive second line lung cancer setting.

Divarasib now enters claiming superiority over approved therapy. If that holds in the full dataset, the read through is straightforward. Genentech takes the lead in G12C, Amgen and BMS have to defend franchises that were already underwhelming, and the bar for any follow on G12C program rises. The nuance to watch is the magnitude of benefit and the safety profile, because a marginal edge changes prescribing far less than a decisive one.

The bigger picture is the two track RAS story. Genentech is going narrow and deep on G12C, the single most common druggable KRAS mutation. Revolution Medicines is going broad with daraxonrasib, a pan RAS approach that hit hard in pancreatic cancer and is heading for a CNPV filing. These are not the same market. G12C is largely a lung cancer story today, while the pan RAS approach opens pancreatic and colorectal disease where the mutations are more varied. The companies that sort out which approach wins in which tumor will define KRAS oncology for the next decade. After forty years of failure, the field suddenly has an embarrassment of riches.

💊 Novartis Bought the Payload, Not the Target

Most ADC dealmaking has focused on targets, the antibody's address label that tells it which cells to hit. HER2, Trop 2, B7-H3, Nectin 4 and the rest. Novartis's Myricx deal is different. The value here is the payload, the toxic warhead the antibody delivers once it arrives.

Current ADC payloads mostly fall into a couple of chemical classes, and tumors develop resistance to them over time. Myricx's platform is built on NMT inhibition, a distinct mechanism of killing cancer cells that could work where existing payloads fail. Pairing a novel payload with established targets like B7-H3 and HER2 is a way to refresh the entire ADC toolkit rather than chase one more target.

This is a smart read of where the ADC field is heading. After years of racing to new targets, the payload has quietly become the bottleneck. As more ADCs reach patients, payload resistance and overlapping toxicity are becoming the limiting factors. Whoever controls a differentiated, resistance breaking payload has leverage across many targets at once. Novartis paying up to $1.5B for a preclinical to early platform tells you how valuable that leverage could be. Expect other large ADC players to go looking for their own payload edge.

📊 A Healthy Reset on AI

Dario Amodei tempering his AI drug discovery predictions is worth more than it might seem. The AI discovery field has run on a specific promise: that machine learning would collapse the timeline and cost of finding drugs. The deals reflect that promise, from Isomorphic's multibillion dollar pacts to Insilico's collaborations with Sanofi, SK Biopharmaceuticals and now Takeda, to the Anthropic ecosystem spanning five of the top pharmas.

The technology is real and already useful in target identification, protein design and molecule optimization. What was never realistic was the compressed timeline. Biology does not speed up just because the chemistry does. You still have to run the trials, and trials take years and fail often. When the CEO of one of the leading AI companies says so out loud, it recalibrates expectations in a useful direction.

For anyone evaluating AI discovery partnerships, the filter is simple. Deals that target the parts of the process AI genuinely accelerates, finding and designing candidates, have a path. Deals sold on the idea that AI will fix the expensive, slow, failure prone clinical stage are running on narrative. The reset Amodei just offered makes it easier to tell the two apart.

Genentech grabbed the lead in KRAS G12C, and the RAS revolution keeps rolling. Novartis paid up for a better ADC payload. And the AI hype got a reality check from the top. This week we are still watching the run up to the July 17 China deadline. What are you watching? Reply to this email.

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →